Our study aimed to identify predictors for the effectiveness of tumor regression in lung cancer patients undergoing neoadjuvant treatment and cancer resections. Patients admitted between 2016 and 2022 were included in the study. Based on the histology of the tumor, patients were categorized into a lung adenocarcinoma group (LUAD) and squamous cell carcinoma group (SQCA). Ninety-five patients with non-small-cell lung cancer were included in the study. A total of 58 (61.1%) and 37 (38.9%) patients were included in the LUAD and SQCA groups, respectively. Additionally, 9 (9.5%), 56 (58.9%), and 30 (31.6%) patients were categorized with a tumor regression score of I, II, and III, respectively. In multivariable analyses, histology of the primary tumor (SQCA), lymph node size in the preoperative CT scan (>1.7 cm), and absolute tumor size reduction after neoadjuvant treatment (>2.6 cm) independently predict effectiveness of tumor regression (OR [95% confidence interval, p-value] of 6.88 [2.40–19.77,p <0.0001], 3.13 [1.11–8.83,p =0.0310], and 3.76 [1.20–11.81,p =0.0233], respectively). Age > 70 years, extended resection > one lobe, and tumor recurrence or metastasis were identified as significant independent predictors of reduced overall survival. Assessment of tumor size before and after neoadjuvant treatment might help to identify high-risk patients with decreased survival and to improve patient management and care.
本研究旨在识别接受新辅助治疗及肿瘤切除术的肺癌患者肿瘤消退有效性的预测因素。研究纳入了2016年至2022年间收治的患者。根据肿瘤组织学类型，患者被分为肺腺癌组（LUAD）和鳞状细胞癌组（SQCA）。研究共纳入95例非小细胞肺癌患者，其中LUAD组58例（61.1%），SQCA组37例（38.9%）。根据肿瘤消退评分，9例（9.5%）、56例（58.9%）和30例（31.6%）患者分别被归为I级、II级和III级。多变量分析显示，原发肿瘤组织学类型（SQCA）、术前CT扫描淋巴结大小（>1.7 cm）以及新辅助治疗后肿瘤绝对缩小程度（>2.6 cm）是肿瘤消退有效性的独立预测因素（比值比[95%置信区间，p值]分别为6.88[2.40–19.77，p<0.0001]、3.13[1.11–8.83，p=0.0310]和3.76[1.20–11.81，p=0.0233]）。年龄>70岁、扩大切除范围超过一个肺叶以及肿瘤复发或转移被确定为总生存期降低的显著独立预测因素。新辅助治疗前后肿瘤大小的评估有助于识别生存率降低的高危患者，从而优化患者管理与临床照护。
肿瘤(癌症)患者之家